Papadopoulos Stelios insider trades
Papadopoulos Stelios has filed 24 Form 4s with the SEC that we hold, for RGLS (Director), Exelixis, INC. (EXEL) (Director), Ovid Therapeutics Inc. (OVID) (Director) and Biogen INC. (BIIB) (Director). Across all of them we count 0 purchases worth $0 and 5 sales worth $7.9M reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($4.4M). The largest single trade was a sale of 100,000 shares of Exelixis, INC. worth $4.4M, dated 2025-11-12. The first filing on our record is dated 2021-07-02 and the latest 2026-05-29.
RGLS
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Exelixis, INC. (EXEL)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-02-22 | S, sale reported on Form 4 | 84,515 | $1.7M | 2022-02-24 |
| 2024-05-20 | S, sale reported on Form 4 | 11,437 | $240.2K | 2024-05-22 |
| 2025-05-15 | S, sale reported on Form 4 | 15,874 | $704.0K | 2025-05-16 |
| 2025-05-15 | S, sale reported on Form 4 | 20,634 | $915.1K | 2025-05-16 |
| 2025-11-12 | S, sale reported on Form 4 | 100,000 | $4.4M | 2025-11-13 |
Ovid Therapeutics Inc. (OVID)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Biogen INC. (BIIB)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1202098) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms